ISPR
Ispire Technology Inc.2.8200
+0.0900+3.3%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q2 '26
Charlie's volumes, bigger deal teased
Q&A delivered specifics on iQTEC's Charlie's partnership, eyeing 2-3 million chips monthly at launch, scaling to 10 million over 12 months, with revenue lift next quarter. Management teased a forthcoming deal of much greater strategic and financial impact. No countries mandate age-gating yet, despite regulator pushes in Southeast Asia, Middle East, and UK. Retailers hunger for flavored vapes as illicit floods persist; Chinese exports surged pre-April VAT hike, but state crackdowns fail to curb demand. iQTEC touts low-friction blockchain edge over rivals. Deals will make or break the inflection thesis.
Key Stats
Market Cap
161.52MP/E (TTM)
-Basic EPS (TTM)
-0.65Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Ispire's Q2 FY2026 revenue fell 51.5% y/y to $20.3M (derived), with Europe at 73% down from prior highs while North America dropped sharply on tighter credit; gross margin slipped to 17.1% from 18.5% on product mix shifts. Operating loss narrowed to $6.9M from $7.4M y/y (derived), aided by 31% lower opex from headcount cuts and less stock comp. Cash burned $5.2M in ops with $17.6M on hand; $1.4M debt matures soon, $29M non-current related-party payable. Credit losses persist. Revenue plunged. FDA PMTA uncertainties loom large.
10-Q
Q1 FY2026 results
Ispire's Q1 FY2026 revenue fell 22.8% y/y to $30.4M, yet gross profit held at $5.1M (17.0% margin, down from 19.5%) while operating loss narrowed to $2.7M from $5.3M, thanks to 39% cuts in opex—mainly lower stock comp and headcount. Net loss improved to $3.3M ($0.06/share) versus $5.6M ($0.10/share), confirmed against 57.3M diluted shares; no anti-dilution. Cash dipped to $22.7M q/q on $1.2M operating outflow, with $1.7M total debt and hefty related-party payables. Europe drove 68% of sales. Credit losses loom large.
10-K
FY2025 results
Ispire Technology posted FY2025 revenue of $127.5M, down 16% y/y from $151.9M, with Europe surging to 58% of sales at $74.1M (up from 43%) while North America cratered to $32.6M from $63.1M amid U.S. cannabis woes. Gross margins slipped to 17.8% from 19.6% on product mix shifts, fueling a net loss swing to $39.2M ($0.69/share) from $14.8M ($0.27/share), hammered by $22M credit loss provisions on receivables. Q4 ramped OEM e-cigarette production in Malaysia, priming 2026 growth. Cash burned to near-zero working capital. Revenue plunged. Regulatory flux threatens nicotine sales momentum.
8-K
Annual meeting elects directors
Ispire Technology held its annual stockholder meeting on June 24, 2025, electing Tuanfang Liu, Jiangyan Zhu, Christopher Robert Burch, Brent Cox, and John Fargis as directors for one-year terms. Stockholders ratified Marcum Asia LLP as independent auditors for the fiscal year ending June 30, 2025, with near-unanimous support from 49.6 million votes for and just 7,657 against. Board continuity locked in.
8-K
Malaysia nicotine license approved
Ispire Technology secured Malaysia's first interim license for nicotine product manufacturing on May 22, 2025, approved by federal and state authorities. Manufacturing starts immediately, expanding from six to 80 production lines soon. This sole authorization de-risks production amid geopolitical pressures. Final license expected in coming months.
IPO
Employees
Sector
Industry
ASBP
Aspire Biopharma Holdings, Inc.
0.10-0.00
BSPK
Bespoke Extracts, Inc.
0.20+0.00
BTI
British American Tobacco Indus
57.29-0.45
IIPR
Innovative Industrial Propertie
58.14+1.61
INSP
Inspire Medical Systems, Inc.
115.51-3.75
PM
Philip Morris International Inc
157.95-0.46
RLX
RLX Technology Inc.
2.37-0.03
TOBAF
TAAT Global Alternatives Inc.
0.04+0.00
TPB
Turning Point Brands, Inc.
110.86+1.25
VPRB
VPR Brands, LP
0.02+0.00